Results 81 to 90 of about 75,915 (258)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Defining CYP3A4 Structural Responses to Substrate Binding. Raman Spectroscopic Studies of a Nanodisc-incorporated Mammalian Cytochrome P450 [PDF]

, 2011
Resonance Raman (RR) spectroscopy is used to help define active site structural responses of nanodisc-incorporated CYP3A4 to the binding of three substrates: bromocriptine (BC), erythromycin (ERY), and testosterone (TST).
Denisov, Ilia G., Grinkova, Yelena V., Kincaid, James R., Mak, Piotr J., Sligar, Stephen G.   +4 more
core   +3 more sources

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Stefan Böhringer, Esther H. M. van Egmond, Peter A. von dem Borne, Jesse J. Swen   +6 more
wiley   +1 more source

CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

The Journal of toxicological sciences, 2013
Effects of the CYP3A4 intron 6 C>T (CYP3A4*22) polymorphism, which has recently been reported to have a critical role in vivo, were investigated by measuring CYP3A4 protein expression levels and CYP3A4-dependent drug oxidation activities in individual human liver microsomes in vitro.
Maho, Okubo, Norie, Murayama, Makiko, Shimizu, Tsutomu, Shimada, F Peter, Guengerich, Hiroshi, Yamazaki   +5 more
openaire   +2 more sources

In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes

Pharmaceutical Biology, 2020
Context Cepharanthine (CEP) extracted from the roots of Stephania cepharantha Hayata (Menispermaceae), has a range of therapeutic potential in clinical conditions.
Xunge Zhang, Ping Feng, Xinfu Gao, Bin Wang, Chunxia Gou, Ruimin Bian   +5 more
doaj   +1 more source

Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms [PDF]

, 2012
BACKGROUND AND PURPOSE Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drugdrug interactions.
Alexander, Arnold, Asimus, Auerbach, Auerbach, Baes, Berman, Blättler, Burk, Burk, di Masi, Dring, Elsherbiny, Faucette, Gautam, Giao, Grace, Halgren, Hesse, Hoffart, Honda, Huey, Hustert, Jyrkkärinne, Kawamoto, Kerb, Khoo, Krey, Kyle, Lee, Maglich, Moore, Morris, Navaratnam, Nussler, Pan, Pissios, Ross, Sanner, Simonsson, Skinner-Adams, Svensson, Svärd, Wang, Ward, White, WHO, WHO, Windshügel, Wolbold, Xu, Zhang   +51 more
core   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro

Drug Design, Development and Therapy, 2017
Ping Fang,1 Peng-fei Tang,1 Ren-ai Xu,2 Xiang Zheng,1 Jian Wen,1 Su-su Bao,1 Jian-ping Cai,3 Guo-xin Hu1 1Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, 2Department of Pharmacy, The First Affiliated Hospital of Wenzhou ...
Fang P, Tang P, Xu R, Zheng X, Wen J, Bao S, Cai J, Hu G   +7 more
doaj  

Influence of verapamil on the pharmacokinetics of oridonin in rats

Pharmaceutical Biology, 2019
Context: Oridonin has been traditionally used in Chinese treatment of various cancers, but its poor bioavailability limits its therapeutic uses. Verapamil can enhance the absorption of some drugs with poor oral bioavailability.
Jing Liu, Ning Zhang, Na Li, Xiaocheng Fan, Ying Li   +4 more
doaj   +1 more source

Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]

, 2018
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez, C Varenhorst, D Alexopoulos, D Aradi, D Lindholm, D Zhou, EA Amsterdam, F Franchi, G Parodi, G Parodi, H Sillén, HS Smith, J Kubica, J Kubica, J Li, JH Cornel, JM Siller-Matula, K Butler, K Butler, K Thygesen, M Koziński, M Roffi, P Adamski, P Adamski, P Adamski, P Adamski, P Niezgoda, P Niezgoda, PG Steg, PG Steg, PT O’Gara, R Teng, R Teng, R Teng, R Teng, R Teng, R Teng, RA Lange, S Husted, S James, SE Husted, SS Brar   +41 more
core   +2 more sources